newsfilter
← Latest News
PR Newswire·

Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the oral presentation of the Phase III study results of denifanstat (ASC40) for...